Application Ser. No.: 10/500,015

Filing Date: June 23, 2004

Examiner: Owens, Amelia A.

Remarks 1

In the Notice of Allowance, the Examiner noted that claims 1 to 6 are allowed.

By this amendment, claim 1 has been amended in order to disclaim three of the

compounds which appear to have been disclosed in WO 95/03306, see specifically,

compound nos. 452-1, 452-2 and 452-3, Table 16, page 35. Please note that all of these

three compounds read on compound of formula (I) when R = fluorine, chlorine or

bromine and when both of the two carbon-carbon bonds represented by ---- are single

bonds. Thus it is respectfully submitted that no new subject matter has been inserted

through these amendments. All of the amendments are fully supported by the

specification. It is further submitted that claim 1, as amended, is still in condition for

allowance, and claims 2-5 have already been allowed.

Supplemental Information Disclosure Statement

Applicants concurrently submit herewith a supplemental IDS along with Form

1449 which lists the above noted WO 95/03306 reference. Entry of which into record is

respectfully requested. Applicants also request an initialed copy of Form 1449 for

Applicants' records.

**Conclusions** 

In view of the above Remarks, it is respectfully submitted that claim 1, as

amended, and claims 2 to 6 are now in condition for allowance and the early issuance of

this case is respectfully requested. In the event the Examiner wishes to contact the

undersigned regarding any matter, please call (collect if necessary) the telephone number

listed below.

As noted above, Applicants are concurrently filing a request for continued

examination (RCE) with this submission along with a supplemental IDS. Applicants

SSL0046 US PCT

-4 of 5-

Application Ser. No.: 10/500,015 Filing Date: June 23, 2004 Examiner: Owens, Amelia A.

request the Commissioner to charge these fees and any other fees that are deemed necessary due to this submission to Deposit Account No. 18-1982 for sanofi-aventis U.S. LLC, Bridgewater, NJ. Please credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

lacem

October 30, 2006

Balaram Gupta, Ph. D., J. D. Registration No. 40,009 Attorney for Applicants

Enclosures: RCE transmittal (1 page)

Supplemental IDS (3 pages)

sanofi-aventis U.S. LLC US Patent Operations Route #202-206 / P.O. Box 6800 MAIL CODE: BWD-303A

Bridgewater, NJ 08807-0800 Telephone: 908-231-3364

Telefax: 908-231-2626